P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
OAB-052: Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
Paul G. Richardson,Aurore Perrot,Jesús F. San Miguel,Meral Beksac,Ivan Spicka,Xavier Leleu,Fredrik Schjesvold,Philippe Moreau,Meletios A. Dimopoulos,Jeffrey Shang Yi Huang,Jiri Minarik,Michele Cavo,H. Miles Prince,Laure Malinge,Franck Dubin,Mony Chenda Morisse,Kenneth C. Anderson +16 more
Journal ArticleDOI
Fish evacuate smoothly respecting a social bubble
Journal ArticleDOI
P-284: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized Phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
Kwee Yong,Philippe Moreau,Meletios A. Dimopoulos,Joseph R. Mikhael,Marcelo Capra,Thierry Facon,Roman Hájek,Ivan Spicka,F. Casca,Sandrine Macé,Marie-Laure Risse,Thomas Martin +11 more
Journal ArticleDOI
MM-064 Updated Progression-Free Survival and Depth of Response in IKEMA, a Randomized Phase 3 Trial of Isatuximab, Carfilzomib, and Dexamethasone (Isa-Kd) Versus Kd in Relapsed Multiple Myeloma.
Thomas Martin,Meletios A. Dimopoulos,Joseph R. Mikhael,Kwee Yong,Marcelo Capra,Thierry Facon,Roman Hájek,Ivan Spicka,F. Casca,Sandrine Macé,Marie-Laure Risse,Philippe Moreau +11 more
TL;DR: In this article , the anti-CD38 antibody Isa in combination with Kd is approved in various countries for relapsed multiple myeloma (MM) patients after ≥1 prior therapy based on primary interim analysis (IA) of the Phase 3 IKEMA study (NCT03275285).
Journal ArticleDOI
Post-CAR T-Cell Early Reconstitution of Peripheral T-Cell Subsets Is Heterogeneous and Independent of the Cell Therapy Outcome in High Grade B-Cell Lymphoma
Baptiste Le Calvez,Yannick Le Bris,Thomas Gastinne,Viviane Dubruille,Beatrice Mahe,Nicolas Blin,Anne Lok,Sophie Vantyghem,C. Sortais,Cyrille Touzeau,Steven Le Gouill,Philippe Moreau,Patrice Chevallier,Marion Eveillard,Marie C. Béné,Benoit Tessoulin +15 more
TL;DR: In this article , the authors used the Kaluza software (Beckman Coulter, Miami, FL) to analyze the percentage of peripheral CD3+, CD4+ and CD8+ lymphocytes over the first 10 days post CAR T-cell infusion for patients with high grade B-cell lymphoma.